TY  - JOUR 
AU  - Valldeoriola Serra, Francesc
AU  - Catalán, María José
AU  - Escamilla-Sevilla, Francisco
AU  - Freire, Eric
AU  - Olivares Romero, Jesús
AU  - Cubo Delgado, Esther
AU  - Calopa, Matilde
AU  - Martínez Martín, Pablo
AU  - Parra, Juan Carlos
AU  - Arroyo, Gloria
AU  - Arbelo, José Matías
PY  - 2021
UR  - http://hdl.handle.net/10259/8807
AB  - Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effect of LCIG on Advanced Parkinson’s...
LA  - eng
PB  - Springer Nature
KW  - Sistema nervioso-Enfermedades
KW  - Nervous system-Diseases
KW  - Medicina
KW  - Medicine
KW  - Neurología
KW  - Neurology
TI  - Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
DO  - 10.1038/s41531-021-00246-y
T2  - npj Parkinson's Disease
VL  - 7
ER  -